BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Business Wire•24/10/2026•04:15 ET
8
Key Highlights
- ➤BGB-B2033 achieved 36.0% confirmed ORR at the recommended Phase 3 dose
- ➤BGB-B2033 six-month confirmed duration-of-response rate estimated at 74.1%
- ➤BGB-58067 produced 25.3% confirmed ORR in MTAP-deficient NSCLC
- ➤BG-C477 delivered 56.0% confirmed ORR in CEA(high) NSCLC
- ➤KANDELA-302 Phase 3 trial began enrolling first-line HR+/HER2-negative breast cancer patients
Expert Statements
Mark Lanasa, Chief Medical Officer, Solid Tumors at BeOne
“At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongside the global Phase 3 KANDELA-302 study of our CDK4 inhibitor in breast cancer, these advances mark a clear step forward as BeOne’s solid tumor pipeline moves from promising science toward medicines with the potential to improve outcomes in difficult-to-treat cancers.”
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer
Get started
Create a free account to read the full story.